Mondelinge presentaties
Du Four S, Maenhout SK, Niclou SP, Thielemans K, Neyns B, Aerts JA. Axitinib, a selective VEGFR-1,-2,-3 tyrosine kinase inhibitor, increases infiltration of immune cells in an intracranial and subcutaneous melanoma mouse model. BACR meeting 2014.
Du Four S, Maenhout SK, Niclou SP, Thielemans K, Neyns B, and Aerts J. Axitinib, a selective VEGFR-1,-2,-3 tyrosine kinase inhibitor inhibits tumor growth and increases infiltration of immune cells in an intracranial mouse melanoma model. 11th meeting of the European association of neuro-oncology (EANO), October 9-12, 2014, Turin, Italy.
Du Four S, Van Der Veken J, Wanet T, Moens M, Duerinck J, Glasker S, Van Velthoven V. Short term outcome of minimal invasive treatment of hemorrhagic stroke. Annual Scientific Meeting of the Belgian Society of Neurosurgery. 2018, Brussels, Belgium